A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Sofituzumab vedotin (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors Genentech
- 01 Nov 2016 Results published in the Annals of Oncology.
- 18 Apr 2014 Status changed from recruiting to completed as completed by ClinicalTrials.gov record.
- 26 Nov 2013 Planned end date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.